Courtesy of Covidien

Minneapolis, USA and Dublin, Ireland - June 15, 2014

• Creates a Medical Technology and Services Company with a Comprehensive Product Portfolio and Broad Global Reach that is Better Able to Improve Healthcare Outcomes

• Meaningfully Accelerates Medtronic's Core Strategies of Therapy Innovation, Globalization and Economic Value

• Combined Revenue of $27 Billion, including $3.7 Billion from Emerging Markets

• Transaction Expected to be Accretive to Medtronic Cash Earnings in FY2016 and Significantly Accretive thereafter

• Medtronic Commits to $10 Billion in Additional U.S. Technology Investments Over 10 Years

Medtronic, Inc. (NYSE: MDT), a global leader in medical technology, services and solutions, and Covidien plc (NYSE: COV), a global healthcare technology and medical supplies provider, today announced that they have entered into a definitive agreement under which Medtronic has agreed to acquire Covidien in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic's closing stock price of $60.70 per share on June 13, 2014.

Courtesy of Covidien

Once the transaction is completed, Medtronic will have significantly advanced its position as the world's premier medical technology and services company.

The combined company will have a comprehensive product portfolio, a diversified growth profile and broad geographic reach, with 87,000 employees in more than 150 countries.

The Boards of Directors of both companies have unanimously approved the transaction.

Courtesy of Covidien

"We are excited to reach this agreement with Covidien, which further advances our mission to alleviate pain, restore health and extend life for patients around the world," said Omar Ishrak, Chairman and Chief Executive Officer of Medtronic.
"This acquisition will allow Medtronic to reach more patients, in more ways and in more places. Our expertise and portfolio of services will allow us to serve our customers more efficiently and better address the demands of the current healthcare marketplace. We also look forward to welcoming the Covidien team to Medtronic and working together to improve healthcare outcomes globally."

Courtesy of Covidien

"Covidien and Medtronic, when combined, will provide patients, physicians and hospitals with a compelling portfolio of offerings that will help improve care and surgical performance," said José E. Almeida, Chairman, President and Chief Executive Officer of Covidien.
"This transaction provides our shareholders with immediate value and the opportunity to participate in the significant upside potential of the combined organization. I'd like to thank our 38,000 employees whose hard work and dedication has enabled Covidien to deliver innovative health solutions that improve patient outcomes."

Courtesy of Covidien

Strategic Rationale

The combination with Covidien supports and accelerates Medtronic's three fundamental strategies:

• Therapy Innovation: With its expanded portfolio of innovative products and services, Medtronic will be a preeminent leader in delivering therapy and procedural innovations to address the major disease states impacting patients and healthcare costs around the world.
Covidien has an impressive portfolio of industry- leading products that enhance Medtronic's existing portfolio, offer greater breadth across clinical areas, and create exciting entry points into new therapies.

• Globalization: With a presence in more than 150 countries, the combined entity will be better able to serve global market needs.
Medtronic and Covidien have combined revenues of $13 billion from outside the U.S., of which $3.7 billion comes from emerging markets.
Covidien's extensive capabilities in emerging market R&D and manufacturing, joined with Medtronic's demonstrated clinical expertise across a much broader product offering, significantly increases the number of attractive solutions the new company will be able to offer to governments and major providers globally.

• Economic Value: Medtronic has adopted an intense focus on aligning with its customers to create more value in healthcare systems around the world - in various delivery and payment systems - by combining products, services and insights into solutions aimed at expanding access and reducing healthcare costs.
With Covidien, Medtronic will be able to provide a broader array of complementary therapies and solutions that can be packaged to drive more value and efficiency in healthcare systems.
Both companies' deep relationships with healthcare system stakeholders will provide enormous ability to identify and create further value-based solutions.

Courtesy of Covidien

U.S. Investment Commitment as a Result of Combination

The U.S. is home to the global medtech industry, one of the most innovative global industries centered in the U.S., and medical devices are among the most valuable U.S. exports.

The combined company is strongly committed to the U.S. as a healthcare innovator, strategic business partner and employer of choice.

Surgical Technologies. NIM-Response Nerve Monitoring System. Courtesy of Medtronic

As a direct benefit of the company's new financial structure, Medtronic will commit to $10 billion in technology investments over the next 10 years in areas such as early stage venture capital investments, acquisitions and R&D in the U.S., above and beyond Medtronic's and Covidien's existing plans.

Surgical Technologies. Integrated Power Console (IPC® System). Courtesy of Medtronic

"The medical technology industry is critical to the U.S. economy, and we will continue to invest and innovate and create well-paying jobs," said Mr. Ishrak.
"Medtronic has consistently been the leading innovator and investor in U.S. medtech, and this combination will allow us to accelerate those investments. These investments ultimately produce new therapy and treatment options that improve or save lives for millions of people around the world."

Surgical Technologies. Fusion™ ENT Navigation System. Courtesy of Medtronic

Structure and Governance

After the completion of the transaction, the businesses of Medtronic and Covidien will be combined under a new entity to be called Medtronic plc.

It will have its principal executive offices in Ireland, where Covidien's current headquarters resides and where both companies have a longstanding presence.

Medtronic plc will be led by Mr. Ishrak, and will continue to have its operational headquarters in Minneapolis, where Medtronic currently employs more than 8,000 people.

Surgical Technologies. O-Arm and Stealth Station together. Courtesy of Medtronic

Financial Highlights

Upon completion of the transaction, each outstanding ordinary share of Covidien will be converted into the right to receive $35.19 in cash and 0.956 of an ordinary share of Medtronic plc.

The per-share consideration represents a premium of 29% to Covidien's closing stock price on June 13, 2014, the last trading day prior to the announcement.

Cardiac Rhythm Disease Management. Viva S CRT-D right view. Courtesy of Medtronic

Medtronic shareholders will exchange each share of stock they own in Medtronic for one ordinary share of stock in Medtronic plc.

The transaction is expected to be taxable, for U.S. federal income tax purposes, to shareholders of both Medtronic and Covidien.

The proposed transaction represents compelling value to Covidien shareholders through the cash component and continued participation in the future growth prospects expected to result from the combination through their ownership of approximately 30% of the combined company.

Cardiac Rhythm Disease Management. Evera S VR ICD with Sprint Quattro Secure leads. Courtesy of Medtronic

The transaction is expected to be accretive to Medtronic's cash earnings in FY 2016, the first full fiscal year, and significantly accretive thereafter.

The transaction is also expected to be accretive to GAAP earnings by FY 2018.

The statement that this acquisition is earnings accretive should not be interpreted to mean that the earnings per share in the current or any future financial period will necessarily match or be greater than those for the relevant preceding financial period.

Cardiac Rhythm Disease Management. Advisa DR MRI™ SureScan® pacing system. Courtesy of Medtronic

The combination is expected to result in at least $850 million of annual pre-tax cost synergies by the end of fiscal year 2018.

These synergies include the benefits of optimizing global back-office, manufacturing and supply-chain infrastructure, as well as the elimination of redundant public company costs.

The estimate excludes any benefit from potential revenue synergies resulting from the combination of the two organizations.

Through this combination, Medtronic is expected to generate significant free cash flow, which it will be able to deploy with greater strategic flexibility, particularly in the U.S.

Neuromodulation. MYStim programmer front view. Courtesy of Medtronic

The consummation of the transaction is subject to certain conditions, including approvals by Medtronic and Covidien shareholders.

In addition, the proposed transaction requires regulatory clearances in the U.S., the E.U., China and certain other countries.

The transaction is expected to close in the fourth calendar quarter of 2014 or early 2015.

Neuromodulation. Restore Sensor front view with leads. Courtesy of Medtronic

Medtronic's financial advisor is Perella Weinberg Partners LP and its legal advisors are Cleary Gottlieb Steen & Hamilton LLP and A & L Goodbody.

Covidien's financial advisor is Goldman, Sachs & Co. and its legal advisors are Wachtell, Lipton, Rosen & Katz and Arthur Cox.

Bank of America Merrill Lynch provided committed financing for the transaction.

For more information about the transaction, please go to www.globalmedtechleader.com 

The announcement required under the Irish Takeover Rules (a Rule 2.5 announcement) has been made and is available at the above-listed website and at www.medtronic.com  


About Medtronic

Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.

Medtronic, Inc. ( www.medtronic.com ), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Medtronic, Inc. World Headquarters in Minneapolis, USA. Courtesy of Medtronic

Medtronic is the world’s leading medical technology company, with more than $16 billion in annual revenue, and operations reaching more than 120 countries worldwide.


About Covidien

Covidien is a global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.

Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products.

With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries.

Please visit www.covidien.com  to learn more about Covidien's business.


Contacts:

Rob Clark
VP, Global Communications
+1-763-505-2682
rob.clark@medtronic.com  

Fernando Vivanco
Sr. Dir., Global Communications
+1-763-505-3780
fernando.vivanco@medtronic.com  

Jeff Warren
VP, Investor Relations
+1-763-505-2696
jeff.warren@medtronic.com  

Peter Lucht
VP, External Communications
+1-508-452-4168
peter.lucht@covidien.com  

Lisa Clemence
Dir., Corporate Communications
+1-508-452-4375
lisa.clemence@covidien.com  

Coleman Lannum, CFA
VP, Investor Relations
+1-508-452-4343
cole.lannum@covidien.com  

Todd Carpenter
Sr. Dir., Investor Relations
+1-508-452-4363
todd.carpenter@covidien.com  



Omar Ishrak

Chairman and Chief Executive Officer of Medtronic

Omar Ishrak Courtesy of Medtronic

Omar Ishrak has served as Chairman and Chief Executive Officer of Medtronic since June 2011.

Medtronic is the world’s leading medical technology company, with more than $16 billion in annual revenue, and operations reaching more than 120 countries worldwide.

Medtronic provides therapies that are used to treat a wide range of conditions, including cardiac and vascular diseases, diabetes, neurological and spinal conditions, and more.

The Medtronic Mission is to alleviate pain, restore health, and extend life for millions of people around the world.

Omar joined Medtronic from General Electric Company, where he spent 16 years, most recently as President and CEO of GE Healthcare Systems, a $12 billion division of GE Healthcare, with a broad portfolio of diagnostic, imaging, patient monitoring and life support systems.

Omar also served as an Officer and a Senior Vice President of GE.

Earlier in his career, Omar amassed 13 years of technology development and business management experience, holding leadership positions at Diasonics/Vingmed, and various product development and engineering positions at Philips Ultrasound.

He grew up in Bangladesh, earned a Bachelor of Science Degree and Ph.D. in Electrical Engineering from the University of London, King's College.

Omar is a member of the Board of Trustees of the Asia Society and is also on the Health Leadership Council of the Save the Children Foundation.


Source: Medtronic, Inc.

http://newsroom.medtronic.com/phoenix.zhtml  



ASTROMAN Magazine - 2014.06.11

Skybox Imaging has entered into an agreement to be acquired by Google

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1729  


ASTROMAN Magazine - 2014.06.09

Polish Company ORLEN acquires Birchill Exploration, new production assets in Canada, doubling its oil and gas reserves

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1728  


ASTROMAN Magazine - 2014.06.06

Atos to acquire Bull to create a European global leader in Cloud, Cybersecurity, and Big Data

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1725  


ASTROMAN Magazine - 2014.06.01

Apple to Acquire Beats Music & Beats Electronics for a total of $3 Billion

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1721  


ASTROMAN Magazine - 2014.05.01

GE offers $16.9 Billion to acquire Alstom Thermal, Renewables, and Grid businesses

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1705  


ASTROMAN Magazine – 2014.04.13

Vodafone acquires 100% of Vodafone India for GBP 1.0 billion

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1695  


ASTROMAN Magazine – 2014.03.28

Intel Corporation and Cloudera announced a broad strategic technology and business collaboration

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1685  


ASTROMAN Magazine – 2014.03.26

Facebook to Acquire Oculus for $2 Billion

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1684  


ASTROMAN Magazine – 2014.02.20

Facebook to Acquire WhatsApp for $19 Billion

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1658  


ASTROMAN Magazine – 2014.02.02

Renault and Nissan launch projects to accelerate Alliance synergies

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1649  


ASTROMAN Magazine – 2014.02.01

Larry Page, CEO, Google: Lenovo to acquire Motorola Mobility for $2.91 billion

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1647  


ASTROMAN Magazine – 2013.12.27

Sale of Gracenote, Inc. by Sony Corporation of America

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1618  


ASTROMAN Magazine – 2013.12.22

IBM to Acquire Aspera to Help Companies Speed Global Movement of Big Data

http://www.astroman.com.pl/index.php?mod=magazine&a=read&id=1610